Novartis AG Says Anything is Possible in Regards to Selling Its Struggling Alcon Biz
Novartis (NOVN.S) cannot rule out selling its Alcon eye care and surgery equipment division, its chief lawyer said on Thursday, helping fan speculation the Swiss drug company could offload a business that has been struggling to revitalize sales.
General Counsel Felix Ehrat told a mergers and acquisitions conference in Zurich that Alcon's position as a leading surgical instruments maker fits Novartis's overall strategy of focusing on divisions which are among the largest players in their respective sectors.
General Counsel Felix Ehrat told a mergers and acquisitions conference in Zurich that Alcon's position as a leading surgical instruments maker fits Novartis's overall strategy of focusing on divisions which are among the largest players in their respective sectors.